Radiation dose reduction to the male gonads during MDCT: the effectiveness of a lead shield.
Our study was designed to quantify the effect of a standard gonad shield on the testicular radiation exposure due to scatter during routine abdominopelvic MDCT. Routine abdominopelvic MDCT was performed in 34 patients with gonadal lead shielding and 32 patients without this shielding; the testes were not exposed to the direct beam during the examination. We estimated the testicular dose administered with thermoluminescent dosimetry, taking into account each patient's body weight and body mass index (BMI). With a 1-mm lead shield, the mean testicular dose was reduced from 2.40 to 0.32 mSv, a reduction of 87%. The difference was found to be statistically significant (p < 0.0001). No correlation between testicular dose and body weight or BMI was found. Shielding the male gonads reduces the testicular radiation dose during abdominopelvic MDCT significantly and can be recommended for routine use.